Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer

•Anti-CTLA-4 antibody quavonlimab + pembrolizumab was assessed in extensive-stage SCLC.•Encouraging antitumor activity was observed in patients with extensive-stage SCLC.•The combination was tolerable with manageable toxicities. This first-in-human phase I study (NCT03179436) investigated anti–cytot...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2021-09, Vol.159, p.162-170
Hauptverfasser:	Cho, Byoung Chul, Yoh, Kiyotaka, Perets, Ruth, Nagrial, Adnan, Spigel, David R., Gutierrez, Martin, Kim, Dong-Wan, Kotasek, Dusan, Rasco, Drew, Niu, Jiaxin, Satouchi, Miyako, Ahn, Myung-Ju, Lee, Dae Ho, Maurice-Dror, Corinne, Siddiqi, Shabana, Ren, Yixin, Altura, Rachel A., Bar, Jair
Format:	Artikel
Sprache:	eng
Schlagworte:	CTLA-4 antigen Drug therapy, combination Immunotherapy Lung neoplasms Programmed cell death 1 receptor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!